



ACIP COVID-19 Vaccine Safety Technical Sub-Group

Melinda Wharton, MD, MPH

Director, Immunization Services Division

National Center for Immunization & Respiratory Diseases

Centers for Disease Control and Prevention

October 30, 2020

ACIP COVID-19 Vaccine Safety Technical Sub-Group (VaST)

- Organized June 2020
- Composition included independent expert consultants, ACIP members, liaison representatives, federal agency SMEs
- Focus:
 - Prioritized adverse events of special interest (AESI)
 - USG plans for safety monitoring
 - Communication framework

Transition of VaST to a smaller data review group

- Built off lessons learned from H1N1 vaccine safety monitoring
- Consensus that FACA would ensure transparency, independence, and public accountability
- Composition
 - ACIP and NVAC representation
 - 7 independent expert consultants
 - ACIP ex officio members (NIH, FDA, OIDP, CMS, HRSA, IHS)
 - VA and DoD liaison

Post-implementation Objectives

- Review, evaluate, and interpret post-authorization/approval COVID-19 vaccine safety data
- Serve as the central hub for technical SMEs from federal agencies conducting post-authorization/approval safety monitoring to share vaccine safety surveillance data
- Advise on analyses, interpretation, and data presentation
- Liaise with the ACIP COVID-19 Vaccines WG on issues of safety data presentation to the ACIP and application of safety data to policy decisions

Deliverables

- Frequent COVID-19 vaccine safety technical reports for internal ACIP and CDC and federal partner use
- Frequent COVID-19 vaccine safety data summaries for public release

Questions